Sponsor pipeline

Relay Therapeutics clinical trial pipeline

Get alerts when Relay Therapeutics's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
2
Phase 2
1
Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… PIK3CA Mutation Recruiting 2026-10-05
Phase 2
NCT06789913 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children… PIK3CA-Related Overgrowth Spectrum (PROS) Recruiting 2026-08-25
Phase 1
NCT07584226 A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors Advanced NRAS-Mutant Melanoma Recruiting 2026-07-02
NCT05216432 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in… PIK3CA Mutation Recruiting 2025-09-22

Disease areas by active trials

Breast Cancer (2) · Melanoma (1)

Get alerts when Relay Therapeutics's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free